Arthneeti
JP

Jubilant Pharmova Ltd

Q2 FY25Pharmaceuticals & Biotechnology

Jubilant Pharmova Ltd Q2 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book

Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,064
Market cap₹17.0K Cr
P/E43.7
Updated24 Sept 2026
Read3 min read

Based on Jubilant Pharmova Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q2’FY25 total income grew 5% YoY to Rs. EBITDA: Rs.

From Jubilant Pharmova Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Q2’FY25 total income grew 5% YoY to Rs. 1,774 Cr. (Page 53, 57) - Q2’FY25 revenue by segment (Page 57): • Radiopharmaceuticals: Rs. 251 Cr., stable YoY • Radiopharmacies: Rs. 568 Cr., +16% YoY • Allergy Immunotherapy: Rs. 170 Cr., -5% YoY • CDMO Sterile Injectables: Rs. 302 Cr., stable YoY • CRDMO Drug Discovery Services: Rs. 151 Cr., +32% YoY • Generics: Rs. 173 Cr., stable YoY - Q2’FY25 generics achieved profitability with EBITDA margin improvement (Page 47) - Outlook: For H2’FY25, focus on continuing revenue growth momentum and expanding EBITDA margins (Page 72)

2 more points management made on revenue & sales performance

Profitability & Margins

See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Spokane Sterile Injectables Capacity Expansion:
  • Doubling capacity of sterile fill and finish (liquid and lyophilization).
  • Total investment: USD 285 million (including USD 149.6 million US Govt funding).
  • Technology transfer started for Line 3.
  • FDA approval application planned for FY26.
  • Commercial production expected post approval in FY26/FY27.
  • Estimated incremental revenue potential: USD 160–180 million.
  • Aim to fill capacity faster than industry average (3-4 years typical).
  • Montreal Facility:
  • Undergoing corrective and preventive actions (CAPA) post USFDA observations.
  • Expected to restart operations mid Q3 FY25.
  • Generics Roorkee Facility:

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any figures or details related to order book, order inflow, or pending orders. Specific terms such as "order book," "order inflow," or "pending orders" do not appear in the excerpts provided. The focus is primarily on financial performance, clinical trial progress, product launches, market strategies, and financial metrics such as revenue, EBITDA, and net debt to EBITDA ratios. Accordingly, no information on order backlog or order inflows is stated in the presentation.

Jubilant Pharmova Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Jubilant Pharmova Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q2 FY25)

    Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key investor presentation takeaways from Wockhardt

  • Anuh Pharma Ltd (Q2 FY25)

    Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY25 investor presentation — and how it ranks against sec

  • Themis Medicare Ltd (Q2 FY25)

    117.01 Cr, up 11.67% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY25 investor presentation — and how it ranks against sector

  • Lincoln Pharmaceuticals Ltd (Q2 FY25)

    EBITDA**: ₹1,234 crore, up 15% YoY . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY25 investor presentation — and how it ranks aga

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Jubilant Pharmova Ltd Q2 FY25 results?

Q2’FY25 total income grew 5% YoY to Rs. EBITDA: Rs.

What is Jubilant Pharmova Ltd share price analysis?

Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jubilant Pharmova Ltd planning capital expenditure?

Spokane Sterile Injectables Capacity Expansion: - Doubling capacity of sterile fill and finish (liquid and lyophilization).

Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.